Article
Fas-1377 A/G polymorphism in lung cancer.
In vivo (Athens, Greece) - 1 Jan 2000
Gormus Uzay, Ergen Arzu, Yaylim-Eraltan Ilhan, Yilmaz Hulya, Turna Akif, Bozkurt Nilüfer, Isbir Turgay
Abstract excerpt
BACKGROUND: Reduced expression of Fas and/or increased expression of FasL is known to exist in some cancer types including lung cancer, so the Fas/FasL system may play a role in the course of cancer. Lack of cell surface Fas expression is one of the main routes of apoptotic resistance in tumor formation and progression. Functional mutations in the Fas gene that impair apoptotic signal transduction are associated...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.